Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies | SpringerLink
QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda® - ScienceDirect
Keytruda, INN-pembrolizumab
Physicochemical stability of pembrolizumab admixture solution in normal saline intravenous infusion bag | Semantic Scholar
Pembrolizumab (Keytruda®) Pharmacokinetic ELISA | AffinityImmuno
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer | BMC Cancer | Full Text
Pembrolizumab Induced Acute Persistent Airway Disease in a Patient with Recurrent Respiratory Papillomatosis (RRP) - Kathryn Marcus, Daniel J. Lee, Jeffrey S. Wilson, Richard J. H. Smith, Michael Puricelli, 2022
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
KEYTRUDA 25 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours | British Journal of Cancer
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer | NEJM
Frontiers | Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
Frontiers | Functional Characterization of Pembrolizumab Produced in Nicotiana benthamiana Using a Rapid Transient Expression System
IJMS | Free Full-Text | Molecular Farming of Pembrolizumab and Nivolumab
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study - The Lancet Oncology
Trial to evaluate combination of CAR-T and pembrolizumab for metastatic colorectal cancer
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study - The Lancet Oncology
Investigating Crystalline Protein Suspension Formulations of Pembrolizumab from MAS NMR Spectroscopy | Molecular Pharmaceutics
Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022 | American Society of Clinical Oncology Educational Book
Physicochemical stability of pembrolizumab admixture solution in normal saline intravenous infusion bag | Semantic Scholar
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial ...
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study - Ito - 2023 - Cancer Medicine - Wiley Online Library
Keytruda doubled survival in advanced colon cancer compared to chemo' < Pharma < Article - KBR
IJMS | Free Full-Text | Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
Patient survival and clinical response to Pembrolizumab across 12... | Download Scientific Diagram
KEYTRUDA 25 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)
